China’s ‘landmark’ drug pricing guidelines widen biotech profit window: analysts

China's State Council has issued new drug pricing guidelines, described as the most significant in ten years, aiming to incentivize pharmaceutical innovation. Published this month, the guidelines establish a value-based pricing approach for patented innovative drugs, while generic drug prices will be lowered through market competition and volume-based procurement. This new framework seeks to alleviate pricing pressures for both domestic and multinational pharmaceutical companies operating in China. The volume-based procurement model involves the government purchasing drugs in bulk for public hospitals, which previously intensified price competition for international firms. The guidelines are intended to foster a more favorable environment for drug innovation by rewarding it appropriately.